Early Life Environment

DNA methylation mediates the effect of maternal smoking during pregnancy on birthweight of the offspring

Leanne K Küpers,1* Xiaojing Xu,5 Soesma A Jankipersadsing,2,3 Ahmad Vaez,1 Sacha la Bastide-van Gemert,1 Salome Scholtens,1,4 Ilja M Nolte,1 Rebecca C Richmond,6 Caroline L Relton,6 Janine F Felix,7,8,9 Liesbeth Duijts,7,8 Joyce B van Meurs,10 Henning Tiemeier,7 Vincent W Jaddoe,7,8,9 Xiaoling Wang,5 Eva Corpeleijn1 and Harold Snieder1

1Departments of Epidemiology, 2Pulmonology and 3Genetics, and 4LifeLines Cohort Study, University Medical Center Groningen, Groningen, The Netherlands, 5Georgia Regents University, Augusta, Georgia, USA, 6MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK, 7Departments of Epidemiology, 8Pediatrics, 9The Generation R Study Group and 10Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands

*Corresponding author. Department of Epidemiology (FA40), University Medical Centre Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. E-mail: l.k.kupers@umcg.nl

Accepted 12 March 2015

Abstract

Background: We examined whether the effect of maternal smoking during pregnancy on birthweight of the offspring was mediated by smoking-induced changes to DNA methylation in cord blood.

Methods: First, we used cord blood of 129 Dutch children exposed to maternal smoking vs 126 unexposed to maternal and paternal smoking (53% male) participating in the GECKO Drenthe birth cohort. DNA methylation was measured using the Illumina HumanMethylation450 Beadchip. We performed an epigenome-wide association study for the association between maternal smoking and methylation followed by a mediation analysis of the top signals [false-discovery rate (FDR) < 0.05]. We adjusted both analyses for maternal age, education, pre-pregnancy BMI, offspring’s sex, gestational age and white blood cell composition. Secondly, in 175 exposed and 1248 unexposed newborns from two independent birth cohorts, we replicated and meta-analysed results of eight cytosine-phosphate-guanine (CpG) sites in the GFI1 gene, which showed the most robust mediation. Finally, we performed functional network and enrichment analysis.

Results: We found 35 differentially methylated CpGs (FDR < 0.05) in newborns exposed vs unexposed to smoking, of which 23 survived Bonferroni correction (P < 1 × 10−7). These 23 CpGs mapped to eight genes: AHR, GFI1, MYO1G, CYP1A1, NeuroG1, CNTNAP2, FRMD4A and LRP5. We observed partial confirmation as three of the eight CpGs in GFI1 replicated. These CpGs partly mediated the effect of maternal smoking on birthweight (Sobel
Differential methylation of these three GFI1 CpGs explained 12–19% of the 202 g lower birthweight in smoking mothers. Functional enrichment analysis pointed towards activation of cell-mediated immunity. **Conclusions:** Maternal smoking during pregnancy was associated with cord blood methylation differences. We observed a potentially mediating role of methylation in the association between maternal smoking during pregnancy and birthweight of the offspring. Functional network analysis suggested a role in activating the immune system.

**Key words:** Epigenetic epidemiology, epigenome-wide association study, DOHaD, fetal programming, GECKO, ALSPAC, Generation R

---

**Introduction**

It is well known that maternal smoking during pregnancy can cause intrauterine growth restriction and low birthweight. Low birthweight, in turn, has been associated with increased childhood growth and cardiometabolic problems in childhood and adulthood. The development of chronic diseases in adulthood is therefore believed to start during pregnancy as a result of exposure to adverse intrauterine environments, also known as fetal programming. We hypothesized that the long-lasting effects of adverse fetal exposures (e.g. smoking) on birthweight and subsequent cardiometabolic risk are at least partly caused by DNA methylation. Thus, maternal smoking during pregnancy may have adverse health consequences during the offspring’s entire life course via DNA methylation.

In recent studies, tobacco smoke exposure has been associated with DNA methylation changes in smokers. The effect of maternal tobacco smoking during pregnancy on DNA methylation of their offspring has also been investigated in a number of studies using different designs. Several of these studies in offspring investigated global or gene-specific DNA methylation differences, in umbilical cord blood and placental cells. Several studies have used an epigenome-wide association study (EWAS) design, focusing on methylation differences of individual cytosine-phosphate-guanine (CpG) sites. Some EWASs used the 27k chip (Illumina Inc., San Diego, USA) in placental samples or whole blood samples of children and identified methylation of several CpGs to be associated with maternal smoking during pregnancy. Other EWASs used the 450K chip (Illumina Inc., San Diego, USA) to identify changes in methylation associated with maternal smoking during pregnancy. Joubert et al. identified and replicated methylation changes in cord blood of several genes (AHRR, CYP1A1 and GFI1) associated with maternal smoking during pregnancy. More recently, Markunas et al. identified and replicated differential methylation of CpGs in 10 novel genes in whole blood from 889 newborns. Other EWASs studied associations with birthweight. Adkins et al. found no epigenome-wide associations with birthweight, whereas Engel et al. identified 19 CpGs. Interestingly, no studies investigated mediation by methylation in the association between maternal smoking and birthweight or other health-related outcomes.

Therefore, we conducted an EWAS in cord blood to examine the association between maternal smoking during pregnancy and DNA methylation, with the 450K chip. Furthermore, we studied for the first time whether differentially methylated CpGs mediated the effect of smoking on birthweight. Finally, we sought to replicate the most promising mediation findings in two independent birth cohorts, and meta-analysed the results.

**Methods**

**Subjects**

We derived data from GECKO Drenthe, a Dutch population-based birth cohort that studies risk factors associated
with the development of overweight from birth into adulthood. The cohort includes 2874 children born between April 2006 and April 2007. Children have been extensively phenotyped on parental characteristics, pregnancy and delivery, children’s health, nutrition and childhood growth. Data were gathered during pregnancy and at multiple time points during childhood. Maternal and paternal smoking during pregnancy were self-reported and (if available) additional information from obstetricians was used. Directly after delivery, umbilical cord blood was collected from 1565 children and stored at -80°C. DNA was extracted from the buffy coats using the QIAamp96 DNA Blood Kit (QIAGEN). To increase DNA concentration to ≥ 50 ng/µl, all samples were treated with Glycoblue.

From all children in the total cohort with stored cord blood, we selected those that had sufficient DNA of good quality after DNA isolation (DNA concentration ≥ 50 µg/ml). Of those, we excluded non-Dutch newborns, premature newborns (≤37 weeks), twins and those with a mother with (gestational) diabetes. We also excluded children with missing information on these variables, which resulted in n = 1118. Then 447 children were selected because they had information on maternal and paternal smoking during pregnancy and the number of cigarettes smoked by the mother. This resulted in 129 children exposed to maternal smoking and 318 children unexposed to either maternal or paternal smoking. This group of 447 did not differ from the group of 1118 on gestational age, birthweight, maternal educational level or gender. Only the maternal pre-pregnancy BMI of the group of 447 was slightly lower (24.4 vs 25.0 kg/m²). Therefore, we concluded that these 447 were broadly representative of the total cohort. We used the complete exposed group (n = 129) and randomly selected 129 unexposed newborns (of which 3 dropped out during QC), see flowchart in Supplementary Figure S1, available as Supplementary data at IJE online.

This study has been approved by the Medical Ethics Committee of the University Medical Center Groningen, and parents of all participants gave written informed consent.

Genome-wide methylation assay

We used 500 ng DNA per sample to perform methylation analysis. To minimize batch effects, we randomized all samples on sex and exposure status per chip over three 96-well plates. Thus each chip contained three exposed boys, three unexposed boys, three exposed girls and three unexposed girls. In addition, we randomly assigned five control samples of the same male to each plate; two on the first plate, two on the second plate and one on the third plate. We performed bisulphite conversion using the EZ-96 DNA methylation kit (Zymo research Corporation, Irvine, USA). After validating that unmethylated cytosines had converted to thymidines using commercially available bisulphite conversion controls (Zymo Research Corporation, Irvine, USA), we processed the samples using the Infinium HumanMethylation450 BeadChip (Illumina Inc., San Diego, USA). We checked performance of built-in internal quality controls in the Controls Dashboard in the methylation module of GenomeStudio (Illumina Inc., San Diego, USA).

Quality control

For all 485,577 CpGs we calculated beta-values and detection P-values using the Minfi R package. Overall, beta-values ranged from zero to one, showing the level of methylation for each CpG, and detection P-values < 0.05 indicated that the target sequence signal was distinguishable from the background. We performed all quality control steps for the three plates separately. Cluster plots for the betas on the X chromosome showed a clear distinction by sex. Two males were in the female cluster, and were excluded from further analyses. Illumina-suggested background normalization and colour correction were performed. One sample did not meet the criterion of ≥ 99% of the CpGs with detection P-value < 0.05 and was excluded. This resulted in a final sample of 255 children: 129 exposed and 126 unexposed. Control probes, probes on X or Y chromosomes and probes that did not meet our criteria of a detection P-value of < 0.05 in ≥ 99% of the samples were excluded. This resulted in 465,891 remaining CpGs. The five duplicate male control samples (included in each plate) showed high correlations ranging from 0.995 to 0.998, indicating that batch effects were minimal. These five samples were removed from further analyses.

Statistical analyses

We performed all pre-processing steps using R packages SWAN (Subset-quantile Within Array Normalization) and Minfi and linear regression in the R package Limma (Linear Models for Microarray Analysis). 26 We generated basic characteristics, mediation analysis and the volcano plot in Stata v12 (StataCorp, College Station, TX, USA).

Epigenome-wide association (EWAS) analysis

We performed linear regression analyses in Limma comparing the methylation beta values of the exposed with the unexposed group. We adjusted for the following covariates that were selected based on their expected association with
maternal smoking and/or methylation: sex, gestational age, maternal age, pre-pregnancy BMI, educational level, plate number and cell type composition. Sex and gestational age (weeks) were reported by obstetricians. Maternal educational level (low/average vs university educated), maternal BMI before pregnancy (kg/m²) and maternal age (years) were self-reported by the mothers. Missing values on gestational age (n = 2), maternal educational level (n = 3) and maternal pre-pregnancy BMI (n = 8) were imputed with the mean/median to maintain power. Excluding the 10 newborns with ≥1 missing covariate did not alter the results, and since multiple imputation in an EWAS dataset would be computationally burdensome, we present our findings including these 10 samples with single imputed covariate data. Furthermore, the number of participants with missing data was very small, thus substantial bias was unlikely. Additionally, we included plate number to adjust for potential batch effects and we calculated cell type proportions based on the method previously presented by Houseman and colleagues with the dataset presented by Reinius and colleagues. These cell type proportions (B cells, granulocytes, monocytes, NK cells, CD4+ T cells and CD8+ T cells) were included as covariates in the model. As a sensitivity analysis, we also performed our analysis without correction for cell type and even in a crude model without any of the covariates, to test the effect of these covariates on our results. We converted raw P-values to false discovery rates (FDRs) based on Benjamini and Hochberg. We used both FDR < 0.05 (raw P < 7.5 × 10^-6) and Bonferroni corrected P-values (raw P < 1 × 10^-7) as significance thresholds. We tested a dose-response effect of number of cigarettes per day on methylation in the exposed group for those signals with FDR < 0.05.

Mediation analysis

We tested the CpGs with FDR < 0.05 for mediation in the association between maternal smoking during pregnancy and birthweight, using the widely used method of Baron and Kenny and the Sobel test. As shown in Figure 1, mediation was considered to be present when: (i) smoking correlated with methylation level (βa); (ii) smoking correlated with birthweight without adjusting the model for the mediator (βc); (iii) differential methylation correlated with birthweight (βb); (iv) the association between smoking and birthweight decreased upon addition of methylation to the model (βc'); and (v) the Sobel test gave P < 0.05, indicating a decrease in the effect of smoking on birthweight after adjusting for the differentially methylated CpG. For those CpGs showing mediation, we tested the assumption that there is no interaction of the exposure and covariates with

the mediator CpGs. For the mediating CpGs, we further calculated which part of the association between smoking and birthweight could be explained by the mediator using the formula: 

\[ \beta_{c'}/(\beta_{c} + \beta_{c'}) \]

The mediation effect \( \beta_{c'} \) equals \( \beta_{c} - \beta_{c'} \), thus this formula equals:

\[ \beta_{c'} = \beta_{c} - \beta_{c'} \]

Functional network analysis

We performed network and enrichment analysis to facilitate the functional interpretation of our differentially methylated genes using GeneMANIA. To this end, we selected all genes to which the top CpGs (FDR < 0.05) mapped as input, to construct a functional interaction network by adding the 100 most strongly interacting genes. Data resources used by the GeneMANIA algorithm were functional association datasets including genetic interactions, protein-protein, co-expression, shared protein domains and co-localization networks. Functional enrichment analysis of all genes of the constructed interaction network against Gene Ontology (GO) terms was performed to find the most enriched GO terms.

Replication

We performed replication analyses for the top findings of our EWAS and mediation analysis in two independent birth cohorts with 450K methylation data in cord blood samples from Caucasian children: ALSPAC (Avon, UK) and Generation R (Rotterdam, The Netherlands). For the replication analyses, we analysed data of 65 exposed and 613 unexposed offspring in ALSPAC and 110 exposed and 635 unexposed offspring in
Generation R (see Supplementary text and Supplementary Table S1, available as Supplementary data at IJE online). All eight GFI1 CpGs with FDR < 0.05 in the EWAS were taken forward for replication. We limited replication to the GFI1 gene as its CpGs showed the most robust and clearest mediation results and GFI1 was among the genes with the most robust EWAS signals in GECKO. Furthermore, unlike NEUROG1, differential methylation of GFI1 was previously reported to be associated with maternal smoking. Exposure in the replication cohorts was defined as sustained maternal smoking during pregnancy vs no maternal smoking during pregnancy, because this was the most accurate measure of exposure in the replication cohorts. Paternal smoking was adjusted for in the mediation analysis. Except for this additional covariate, mediation analyses were performed using the same analysis protocol as in GECKO. In order to obtain one overall estimate of the results for each of the eight GFI1 CpGs, we used fixed effects inverse variance meta-analysis of the results of the two replication cohorts. Subsequently, we combined results of discovery (GECKO) and replication (ALSPAC and Generation R) stages in a joint meta-analysis. We concluded that mediation was present for CpGs showing a two-sided analysis. We concluded that mediation was present for CpGs showing a two-sided analysis. 

**Results**

General characteristics of all participants in GECKO are presented in Table 1, for characteristics of ALSPAC and Generation R participants see Supplementary Table S1, available as Supplementary data at IJE online. On average, in GECKO, smoking mothers were 1.4 years younger and more often had a lower educational level and their children had a 281 g lower birthweight.

We found 35 CpGs, mapping to 10 genes, that showed differential methylation (FDR < 0.05) between the groups exposed and unexposed to maternal smoking (Table 2). After the more conservative Bonferroni correction, 23 CpGs remained. These 23 CpGs mapped to eight genes: AHRR, GFI1, MYO1G, CYP1A1, NEUROG1, CNTNAP2, FRMD4A and LRP5. All eight CpGs mapping to GFI1, LRP5 and CNTNAP2 had lower methylation levels in the group exposed to maternal smoking during pregnancy compared with the unexposed group (methylation difference (beta value exposed minus beta value unexposed) ranged from –0.021 to –0.117). The 11 CpGs that mapped to MYO1G, NEUROG1, FRMD4A and CYP1A1 had higher methylation levels in the exposed group (methylation difference ranged from 0.028 to 0.077). For AHRR, three CpGs had lower methylation levels (methylation difference between –0.024 and –0.073) whereas one had higher methylation in the exposed group (methylation difference 0.038).

**Table 1. Characteristics of children exposed and unexposed to maternal smoking (n = 255 in GECKO)**

| Characteristics             | Unexposed (n = 126) | Exposed (n = 129) | P_difference |
|-----------------------------|---------------------|-------------------|--------------|
| Male                        | 66 (52.4)           | 70 (54.3)         | 0.76         |
| Birthweight                 | 3685 ± 563          | 3404 ± 464        | <0.0001      |
| Gestational age             | 39.8 ± 1.2          | 39.7 ± 1.3        | 0.18         |
| Maternal age at childbirth  | 31.1 ± 3.6          | 29.7 ± 4.7        | <0.01        |
| Maternal low/middle educational level | 70 (55.6) | 105 (81.4) | <0.0001      |
| Maternal pre-pregnancy BMI  | 23.9 ± 3.3          | 24.9 ± 5.1        | 0.09         |
| Number of cigarettes smoked | NA                  | 10 (1–30)         |              |

Data shown as n (%) or mean ± SD. Except for number of cigarettes smoked: median (range). P-values are given for independent samples t-test (continuous) or chi-square test (categorical).

Unexposed group was defined as no smoking during pregnancy, by mother or by father. Exposed group was defined as smoking during pregnancy by mother.

Effects of covariate adjustment on EWAS results are shown in Supplementary Table S2, available as Supplementary data at IJE online. Analysis without adjustment for cell type distribution did not substantially change our top (Bonferroni significant) findings, but the list of CpGs with FDR < 0.05 decreased substantially after cell type correction.

The volcano plot in Figure 2 shows the methylation differences between the exposed and unexposed groups plotted against statistical significance. It shows the 35 differentially methylated CpGs (FDR < 0.05) and the 23 CpGs that remained statistically significant after Bonferroni correction.

We observed no dose-response effect of number of cigarettes smoked per day on differential methylation in the exposed group for any of the 35 top CpGs (data not shown).

Next, we considered the 35 top CpGs to test for the mediating effect in the association between maternal smoking and birthweight. All CpGs on the growth factor independent 1 transcription repressor (GFI1) gene (eight CpGs) and the neurogenin 1 (NEUROG1) gene (two CpGs) showed mediation with P < 0.07 in GECKO (Table 3), whereas the other CpGs did not (Supplementary Table S3, available as Supplementary data at IJE online). None of these CpGs showed interaction with the exposure or covariates in its effect on birthweight (Supplementary Tables S4a–h, available as Supplementary data at IJE online). We limited replication analysis to CpGs in GFI1 because it showed the most robust results.
Table 2. Top 35 CpGs with methylation difference between children exposed and unexposed to maternal smoking (FDR < 0.05)

| CpG      | Closest gene | Chr  | Bp position | Location in gene | Located in island, shore or open sea | Mean methylation percentage | Methylation difference | P-value |
|----------|--------------|------|-------------|------------------|---------------------------------------|-----------------------------|------------------------|---------|
| cg0575921 | AHRR         | 5    | 373378      | Body             | Shore                                 | 0.688                       | -0.073                 | 1.14E-25 |
| cg04180046 | MYO1G       | 7    | 45002736    | Body             | Island                                | 0.497                       | 0.056                  | 1.10E-14 |
| cg09935388 | GFI1        | 1    | 92947588    | Body             | Island                                | 0.661                       | -0.105                 | 2.67E-14 |
| cg1420911 | NEUROGI1*    | 5    | 13481332    | Open sea         | Open sea                              | 0.690                       | 0.048                  | 7.17E-12 |
| cg14179389 | GFI1        | 1    | 92947961    | Body             | Island                                | 0.188                       | -0.061                 | 1.76E-11 |
| cg12803068 | MYO1G       | 7    | 45002919    | Body             | Shore                                 | 0.759                       | 0.077                  | 1.79E-11 |
| cg12876356 | GFI1        | 1    | 92946825    | Body             | Island                                | 0.660                       | -0.107                 | 1.79E-11 |
| cg01952185 | NEUROGI1*    | 5    | 134813213   | Open sea         | Open sea                              | 0.590                       | 0.047                  | 3.32E-11 |
| cg18146737 | GFI1        | 1    | 92946700    | Body             | Island                                | 0.739                       | -0.117                 | 3.81E-11 |
| cg22132788 | MYO1G       | 7    | 45002486    | Body             | Island                                | 0.881                       | 0.053                  | 1.57E-10 |
| cg23067299 | AHRR         | 5    | 323907      | Body             | Shore                                 | 0.723                       | 0.038                  | 2.66E-10 |
| cg21611682 | LRP5        | 11   | 68138269    | Body             | Open sea                              | 0.519                       | -0.021                 | 2.83E-10 |
| cg18316974 | GFI1        | 1    | 92947035    | Body             | Shore                                 | 0.784                       | -0.102                 | 3.27E-10 |
| cg15503734 | FRMD4A      | 10   | 14372913    | TSS200           | Open sea                              | 0.556                       | 0.028                  | 2.90E-09 |
| cg05549655 | CYP1A1      | 15   | 75019143    | TSS1500          | Island                                | 0.256                       | 0.036                  | 3.20E-09 |
| cg19089271 | MYO1G       | 7    | 45002287    | 3’UTR            | Island                                | 0.796                       | 0.037                  | 3.33E-09 |
| cg11924019 | CYP1A1      | 15   | 75019283    | TSS1500          | Island                                | 0.473                       | 0.036                  | 9.04E-09 |
| cg09662411 | GFI1        | 1    | 92946132    | Body             | Island                                | 0.714                       | -0.066                 | 9.55E-09 |
| cg23594550 | CNTNAP2     | 7    | 145814306   | Body             | Shore                                 | 0.136                       | -0.022                 | 9.84E-09 |
| cg22549041 | CYP1A1      | 15   | 75019251    | TSS1500          | Island                                | 0.304                       | 0.052                  | 1.53E-08 |
| cg14817490 | AHRR         | 5    | 392920      | Body             | Open sea                              | 0.336                       | -0.030                 | 3.98E-08 |
| cg21161138 | AHRR         | 5    | 399360      | Body             | Open sea                              | 0.742                       | -0.024                 | 6.18E-08 |
| cg18092474 | CYP1A1      | 15   | 75019302    | TSS1500          | Island                                | 0.564                       | 0.047                  | 9.24E-08 |
| cg22937882 | AHRR         | 5    | 405774      | Body             | Open sea                              | 0.857                       | 0.016                  | 2.23E-07 |
| cg23456480 | FRMD4A      | 10   | 14372910    | TSS200           | Open sea                              | 0.675                       | 0.025                  | 3.07E-07 |
| cg24159436 | PLC1L2      | 3    | 16974681    | 1stExon          | Open sea                              | 0.622                       | 0.028                  | 1.10E-06 |
| cg04535902 | GFI1        | 1    | 92947332    | Body             | Shore                                 | 0.797                       | -0.057                 | 1.77E-06 |
| cg12101586 | CYP1A1      | 15   | 75019203    | TSS1500          | Island                                | 0.383                       | 0.040                  | 2.11E-06 |
| cg11813497 | FRMD4A      | 10   | 14372879    | TSS200           | Open sea                              | 0.700                       | 0.028                  | 4.01E-06 |
| cg01970407 | AHRR         | 5    | 323320      | Body             | Shore                                 | 0.678                       | 0.023                  | 4.07E-06 |
| cg13834112 | –           | 15   | 90361639    | Shelf            | –                                     | 0.625                       | 0.028                  | 4.54E-06 |
| cg23680900 | CYP1A1      | 15   | 75017924    | TSS200           | Shore                                 | 0.149                       | 0.015                  | 5.01E-06 |
| cg17292337 | –           | 12   | 31272112    | Open sea         | Open sea                              | 0.361                       | -0.098                 | 5.14E-06 |
| cg01264106 | LGALS1      | 22   | 38071602    | TSS200           | Shore                                 | 0.346                       | 0.020                  | 5.78E-06 |
| cg10399789 | GFI1        | 1    | 92945668    | Body             | Shore                                 | 0.738                       | -0.049                 | 7.48E-06 |

Analyses were corrected for plate, sex, gestational age, maternal age, maternal education, maternal BMI and cell type composition. Methylation difference was calculated from the average beta values of exposed minus unexposed groups.

*Closest gene was NEUROG1 (57 411–57 527 bp downstream), all other CpGs were mapped within the boundaries of the given genes.

Replication and meta-analysis in ALSPAC and Generation R confirmed the association with maternal smoking for seven of the eight CpGs in GFI1 and mediation was replicated for three of the eight GFI1 CpGs: cg09935388, cg14179389 and cg12876356 (Table 4). Although not all these CpGs were significant in the two individual replication cohorts, directions of the effects were consistent (Supplementary Table S5, available as Supplementary data at IJE online). Joint meta-analysis of discovery and replication cohorts combined showed that differential methylation of these three GFI1 CpGs explained 12–19% of the 202 g lower birthweight in smoking mothers. For example, this was 19% for cg09935388 calculated as follows: newborns of smoking mothers had a 202 g lower birthweight compared with unexposed newborns (meta-analysis of βc, data not shown). After adding the CpG as mediator in the model, the effect of smoking on birthweight decreased by 37.5 g (βc’ – βc in overall meta-analysis, see Table 4). Therefore, 37.5/202 = 19% of the 202 g lower birthweight in exposed newborns could be explained by mediation through differential methylation.

We observed 28 enriched GO terms (FDR < 0.05) for the 110 genes in the interaction network (Table 5). Most enriched terms are closely related and point towards regulation of immune system processes, particularly the cell-mediated immunity response.
Furthermore, replication analysis confirmed methylation in these CpGs (in eight genes) survived Bonferroni correction. Methylation in the exposed and non-exposed groups; 23 of these CpGs (FDR < 0.05) in 10 genes to be differentially methylated in the exposed and non-exposed groups; 23 of these CpGs (eight genes) survived Bonferroni correction. Furthermore, replication analysis confirmed methylation of three GFI1 CpGs to mediate the association between maternal smoking during pregnancy and decreased birthweight. Finally, functional network analysis showed that the top differentially methylated genes influenced immune system processes, particularly related to cell-mediated immunity.

The association between smoking and methylation is one of the most widely studied epigenetic associations and evidence from EWASs on maternal tobacco smoking and DNA methylation specifically in offspring is accumulating rapidly. EWASs investigating the influence of cigarette smoking have used a variety of DNA sources, including placental cells, and studies in active smokers have been performed in whole blood, peripheral blood, lymphoblast DNA or lung alveolar macrophages with a generally high level of consistency across tissue and studies. To our knowledge only a limited number of EWASs have been published investigating the effect of maternal smoking during pregnancy in offspring using the 450 K chip, of which only one was done in cord blood.

The 23 differentially methylated CpGs mapped to eight genes: AHR, GFI1, MYO1G, CYP1A1, NEUROG1, CNTNAP2, FRMD4A and LRP5. Differential methylation of these genes (except for NEUROG1) was also observed (but not all consistently replicated) in other EWASs in cord and whole blood and/or in other studies into smoking and methylation in adults. Previous studies related methylation in the aryl-hydrocarbon receptor repressor (AHR) gene and the Cytochrome P450, family 1, subfamily A1 (CYP1A1) gene to tobacco smoke exposure in both smokers and newborns and most studies, including ours, reported the same CpG as the top signal (cg05575921). Both AHR and CYP1A1 are involved in the aryl-hydrocarbon receptor (AhR) pathway, regulating the biological responses to hydrocarbons found in cigarette smoke and xenobiotic metabolism in general. The myosin-I G (MYO1G) gene is involved in haematopoietic processes and regulation of cell elasticity. The contactin-associated protein-like 2 (CNTNAP2) gene is involved in the development of the nervous system and in neuropsychiatric disorders. Finally, the low-density lipoprotein receptor-related protein 5 (LRP5) gene plays a role in skeletal homeostasis. Differential methylation of the FERM Domain Containing 4A (FRMD4A) gene has also previously been observed in relation to tobacco smoke exposure in offspring of smoking mothers (in whole blood). Interestingly, single nucleotide polymorphisms in FRMD4A have been shown to be involved in nicotine dependence.

An important finding in our study was the mediating effect of differential methylation of the growth factor independent 1 transcription repressor (GFI1) gene in the association between maternal smoking and birthweight. GFI1 is known to play a role in developmental processes such as haematopoiesis and oncogenesis. Thus, GFI1 could be involved in cellular development and possibly fetal growth. However, it has not previously been linked to birthweight or other anthropometric measures.

Differential methylation of NEUROG1 also seemed to mediate the association between maternal smoking and birthweight in GECKO; however, our discovery results in NEUROG1 await future replication. NEUROG1 is known to be associated with neuronal differentiation and neurogenesis, making a link to fetal development plausible. It should be noted that these CpGs were not mapped within the NEUROG1 gene regions, but located close to this gene (57 k downstream).

To the best of our knowledge, we were the first to investigate and identify statistical evidence of mediation by DNA methylation (in GFI1) in the pathway from maternal tobacco smoking during pregnancy to decreased birthweight of the offspring. Meta-analysis of all three cohorts showed that three CpGs on GFI1 explained between 12% and 19% of the effect of maternal smoking on birthweight. These findings are promising, as this biological mechanism seemed to explain part of the effect of smoking on birthweight. Other mechanisms causing reduced fetal growth
may involve impaired placental perfusion, chronically low levels of fetal oxygen supply, and sensitivity to adipocytokines, e.g. leptin or ghrelin. However, it should be kept in mind that many other factors are involved in intrauterine growth and birthweight, e.g. malnutrition or stress, and that DNA methylation could not explain the total variation in birthweight resulting from smoking. As in any epidemiological study, residual confounding could not be entirely excluded. However, maternal smoking during pregnancy is known to have a direct adverse effect on growth of the fetus and is therefore likely to have a much stronger effect on methylation than other possible confounding factors.

We performed network and enrichment analysis to facilitate the functional interpretation of our 10 differentially methylated genes. Most enriched GO terms were related to immune system processes, especially to those related to cell-mediated immunity. Thus, intrauterine exposure to components in cigarette smoke seemed to elicit an immune response in the offspring. Such an immune response in smokers and offspring of smoking mothers may play a role in the increased risk of developing asthma. This is in line with studies showing that the AhR pathway activates the immune system triggered by environmental exposures such as tobacco smoke, pollutants and diet. Additional research will be needed to show whether these smoking-induced methylation effects may increase the risk of developing autoimmune diseases. These results seemed independent of cell type differences caused by maternal smoking, as we have adjusted all our analyses for these differences, although we cannot entirely exclude that cell correction was incomplete and residual cell (sub)type effects could be possible.

The current study has many strengths. We found that 78% of our top CpG signals overlapped with those from a previous EWAS on the same topic (data not shown), which is a testament to the robustness of our findings. Moreover, cord blood is an excellent tissue to test for methylation differences associated with maternal smoking, because cord blood has not yet been exposed to external influences other than those provided by the intrauterine environment. As such, potential confounding by those external exposures on the newborn is minimized. Use of cord blood to study DNA methylation as a potential mediator of birthweight is less ideal, as it implicitly assumes that it reflects methylation patterns from other tissues such as muscle, fat and bone that might be more plausibly causally related to fetal growth and birthweight. However, such tissues would be prohibitively difficult to collect from newborns and for this reason cord blood is currently the most commonly used tissue in epidemiological studies of newborns. Furthermore, in (epi)genetic epidemiology the winner’s curse is a well-known phenomenon, which means that the effect sizes of newly identified associations are

Table 3. Mediation analysis examining the indirect effect of maternal smoking during pregnancy on birthweight through methylation in GECKO

|                      | $\beta_c$ | SE_c | P_c | R-square | $\beta_b$ | SE_b | P_b | Difference in betas ($\beta_c - \beta_b$) | Mediation percentage ($(\beta_c - \beta_b) / \beta_b$) | Sobel P-value |
|----------------------|----------|------|-----|----------|----------|------|-----|------------------------------------------|------------------------------------------------|--------------|
| BW = smoking + covariates | -264.3   | 59.4 | 1.3E-05 | 0.307    |          |      |     |                                          |                                                |              |
| BW = smoking + CpG + covariates | $\beta_c'$ | $\beta_b$ | SE_c | SE_b | P_c | P_b | Difference in betas ($\beta_c' - \beta_b$) | Mediation percentage ($(\beta_c' - \beta_b) / \beta_b$) | Sobel P-value |

GFI1

cg09935388  
$cg14179389$  
$cg12876356$  
$cg18146737$  
$cg18316974$  
$cg09662411$  
$cg04535902$  
$cg10399789$  

cg11429111  
$cg01952185$

BW, birthweight.
Covariates: plate, sex, gestational age, maternal age, maternal education, maternal BMI and cell type composition.
Sobel test = $\beta_c - \beta_b / \text{SE}$, where $\text{SE} = \sqrt{\beta_c^2 \times \text{SE}_{\beta_c}^2 + \beta_b^2 \times \text{SE}_{\beta_b}^2}$.
The coefficients $\beta_c$ and $\beta_b$ can be interpreted as the amount of grams lower birthweight for smoking vs non-smoking mothers in the 'smoking to birthweight' and full model, respectively. $\beta_b$ represents the effect of methylation level (coded as a proportion between 0–1) on birthweight. For cg09935388 this means that an increase of 100% in methylation level is associated with 1190.4 g higher birthweight. For extra information on the betas, see Figure 1.
often overestimated in the discovery cohort. For this reason we reported effect sizes of the combined analyses of discovery and replication cohorts, which showed only partial replication of our discovery findings. We were able to replicate three of the eight mediating CpGs in two other cohorts, which confirmed and strengthened our results. However it should be kept in mind that not all CpGs replicated and those CpGs that did replicate did not show such strong mediation as in the discovery sample. Another strength was the inclusion of the mediation analysis, giving more insight into the biological pathway between maternal smoking and birthweight.

To our knowledge, this is the first study to formally assess and report this mediating effect of DNA methylation. Additionally, we gave a functional interpretation of our results using functional network and enrichment analyses, which indicated that the differentially methylated genes play a role in activation of immune system processes. Finally, we used the Houseman correction with the Reinius dataset, a popular method to adjust for differences in cell type distributions between the exposed and unexposed groups of six cell types (B cells, granulocytes, monocytes, NK cells, CD4+ T cells and CD8+ T cells).28,29 This, reassuringly, showed no alterations in our top findings. The top signals still survived Bonferroni correction after cell type correction; however, the larger list of CpGs that survived FDR differed substantially (Supplementary Table S2, available as Supplementary data at IJE online). Consequently, the gene list that was used as input for the network and functional enrichment analysis was also different. Interestingly, the general pattern of results did not change, as we still observed that most enriched terms pointed towards positive regulation of particularly cell-mediated immune responses. Furthermore, the mediation results did not change as we observed significant mediation by the GFI1 gene and not by any of the other genes, before and after cell type correction.

Table 4. Results of meta-analysis (EWAS and mediation model) for GECKO, ALSPAC and Generation R

| CpG           | Discovery GECKO | Replication meta-analysis ALSPAC & Generation R | Overall meta-analysis (disc. + repl.) GECKO, ALSPAC & Generation R |
|---------------|----------------|-----------------------------------------------|---------------------------------------------------------------------|
|               | Methylation difference | P-value | Methylation difference | P-value | Methylation difference | P-value |
| cg09935388    | −0.105          | 2.67E-14 | −0.103                    | 2.30E-19 | −0.104                | 4.61E-32 |
| cg14179389    | −0.061          | 1.76E-11 | −0.064                    | 2.54E-17 | −0.063                | 3.13E-27 |
| cg12876356    | −0.107          | 1.79E-11 | −0.086                    | 1.20E-14 | −0.093                | 2.48E-24 |
| cg18146737    | −0.117          | 3.81E-11 | −0.098                    | 1.24E-14 | −0.105                | 4.53E-24 |
| cg18316974    | −0.102          | 3.27E-10 | −0.060                    | 2.35E-07 | −0.074                | 4.00E-15 |
| cg09662411    | −0.066          | 9.55E-09 | −0.049                    | 8.52E-09 | −0.055                | 8.88E-16 |
| cg04535902    | −0.057          | 1.77E-06 | −0.00925                  | 3.15E-01 | −0.027                | 2.04E-04 |
| cg10399789    | −0.049          | 7.48E-06 | −0.030                    | 3.04E-03 | −0.039                | 1.75E-07 |

Mediation analysis

| CpG           | Discovery GECKO | Replication meta-analysis ALSPAC & Generation R | Overall meta-analysis (disc. + repl.) GECKO, ALSPAC & Generation R |
|---------------|----------------|-----------------------------------------------|---------------------------------------------------------------------|
|               | Δ beta         | Mediation % | Sobel P-value | Δ beta         | Mediation % | Sobel P-value | Δ beta         | Mediation % | Sobel P-value |
| cg09935388    | −121.0 g       | 45.8%      | 0.0003 | −28.7 g       | 16.2%      | 0.0081 | −37.5 g       | 18.6%      | 0.0003 |
| cg14179389    | −49.9 g        | 18.9%      | 0.064  | −21.3 g       | 12.0%      | 0.0436 | −25.1 g       | 12.4%      | 0.0107 |
| cg12876356    | −106.3 g       | 40.2%      | 0.001  | −29.9 g       | 16.8%      | 0.0061 | −38.1 g       | 18.9%      | 0.0002 |
| cg18146737    | −98.7 g        | 37.3%      | 0.001  | −19.6 g       | 11.0%      | 0.1143 | −31.3 g       | 15.5%      | 0.0062 |
| cg18316974    | −86.6 g        | 32.8%      | 0.002  | −3.4 g        | −1.9%      | 0.7032 | −4.7 g        | 2.3%       | 0.5844 |
| cg09662411    | −67.8 g        | 25.7%      | 0.008  | −8.5 g        | 4.8%       | 0.3730 | −15.7 g       | 7.8%       | 0.0788 |
| cg04535902    | −71.0 g        | 26.9%      | 0.002  | 1.5 g         | −0.8%      | 0.8107 | −3.5 g        | 1.7%       | 0.5689 |
| cg10399789    | −47.0 g        | 17.8%      | 0.018  | −4.5 g        | 2.5%       | 0.5237 | −9.4 g        | 4.7%       | 0.1611 |

Disc, discovery; repl, replication.
For all meta-analysis we have used a two-sided \( P < 0.05 \) as significance threshold.
Bold: CpG sites for which significant mediation was confirmed (\( P < 0.05 \) for both replication meta-analysis and overall meta-analysis).

(mediation results before correction are not shown). This method was based on a reference dataset of whole blood samples from adult males, which have a different cell composition from cord blood, and this cell type correction did not account for more specific cell subtypes. However, currently this is the best option because no cord blood reference dataset exists and, even in cord blood, this reference-based cell type correction is the best method available as recently applied by Kile and colleagues.27

In contrast to an earlier study, which observed dose-dependency by maternal cotinine plasma levels, 17 we did not find an effect of the number of cigarettes smoked per day. Joubert et al.17 found a dose-response relationship for two of the significant genes, but not for all top genes. Thus, a dose-response relationship could be expected for some genes but not for all. Another potential reason for the lack of a dose-response relationship in our data is our smaller sample size compared with the study of Joubert et al. which measured smoking status objectively as plasma cotinine levels.17

We found support for our hypothesis that differential methylation mediates part of the effect of smoking on birthweight, but we could not be certain about the direction of causation in this observational study. One possibility is that methylation markers simply provided a better measure of smoking exposure than the self-reported smoking behaviour we used in our study. Such biomarkers would then also be expected to be associated with birthweight. However, the fact that only GFI1 showed significant association with birthweight and not, for example, the AHRR cg05575921 CpG showing the strongest EWAS

| GO ID         | Description                                           | FDR       | Occurrences in sample | Occurrences in genome |
|---------------|-------------------------------------------------------|-----------|-----------------------|-----------------------|
| GO:0046649    | Lymphocyte activation                                 | 1.87e-07  | 16                    | 294                   |
| GO:0042110    | T cell activation                                     | 2.11E-07  | 14                    | 217                   |
| GO:0042101    | T cell receptor complex                               | 3.07E-07  | 6                     | 13                    |
| GO:0050900    | Leukocyte migration                                   | 1.21e-06  | 13                    | 214                   |
| GO:0050851    | Antigen receptor-mediated signalling pathway          | 2.09e-06  | 10                    | 108                   |
| GO:0002429    | Immune response-activating cell surface receptor signalling pathway | 2.98e-06 | 10                    | 114                   |
| GO:0050852    | T cell receptor signalling pathway                    | 3.77E-06  | 9                     | 86                    |
| GO:002768     | Immune response-regulating cell surface receptor signalling pathway | 4.73e-06 | 10                    | 123                   |
| GO:002757     | Immune response-activating signal transduction        | 9.00e-05  | 11                    | 219                   |
| GO:0043235    | Receptor complex                                      | 9.00e-05  | 9                     | 128                   |
| GO:002764     | Immune response-regulating signalling pathway          | 1.29e-04  | 11                    | 229                   |
| GO:0002253    | Activation of immune response                         | 4.75e-04  | 11                    | 263                   |
| GO:0030098    | Lymphocyte differentiation                            | 5.31e-04  | 8                     | 119                   |
| GO:0002696    | Positive regulation of leukocyte activation           | 5.31e-04  | 9                     | 164                   |
| GO:0030217    | T cell differentiation                                | 5.31E-04  | 7                     | 82                    |
| GO:0050867    | Positive regulation of cell activation                | 6.38e-04  | 9                     | 170                   |
| GO:002521     | Leukocyte differentiation                              | 1.66e-03  | 9                     | 192                   |
| GO:0051249    | Regulation of lymphocyte activation                   | 2.02e-03  | 9                     | 198                   |
| GO:0051251    | Positive regulation of lymphocyte activation          | 2.60e-03  | 8                     | 153                   |
| GO:0002274    | Myeloid leukocyte activation                           | 2.71e-03  | 6                     | 70                    |
| GO:0002694    | Regulation of leukocyte activation                    | 4.27e-03  | 9                     | 221                   |
| GO:0050865    | Regulation of cell activation                          | 7.94e-03  | 9                     | 240                   |
| GO:0043230    | Extracellular organelle                               | 1.90e-02  | 5                     | 61                    |
| GO:0070062    | Extracellular vesicular exosome                        | 1.90e-02  | 5                     | 60                    |
| GO:0065010    | Extracellular membrane-bounded organelle              | 1.90e-02  | 5                     | 61                    |
| GO:0002250    | Adaptive immune response                              | 1.95e-02  | 6                     | 103                   |
| GO:0001773    | Myeloid dendritic cell activation                     | 2.63e-02  | 3                     | 12                    |
| GO:0050863    | Regulation of T cell activation                        | 2.63E-02  | 7                     | 162                   |

GO ID, gene ontology identification number.
signal, contradicted this explanation. Another possibility we could not entirely exclude is that retardation of fetal growth expressed as lower birthweight led to differential methylation rather than the other way around. However, we believe this is unlikely given the primary role of epigenetic mechanisms in orchestrating changes in gene expression during growth and development.

We acknowledge that the Baron and Kenny approach for mediation analysis has been criticized among others for its dependency on and sensitivity to measurement errors, misclassification and violation of model assumptions. However, the Infinium HumanMethylation450 BeadChip is a reliable instrument reflecting the state of the art in measurement of genome-wide DNA methylation. Moreover, mediation effects of three CpG sites were independently replicated in cord blood data from two other birth cohorts, in spite of presumably differential measurement errors between the three cohorts. Instability of methylation over time is an additional potentially important source of measurement error that could not be addressed by the cross-sectional design of our study, which only looked at differential methylation at birth. We backed up our mediation results from the Baron and Kenny approach with a more advanced statistical approach, and additionally applied causal mediation analysis to the three replicated CpGs in the GECKO cohort. This analysis uses a more general potential outcomes framework, can provide additional distribution-free estimates of the mediated effects and facilitates sensitivity analyses for the observed effects. Results of these analyses were in line with our Baron-Kenny results and Sobel tests (see Supplementary Note, available as Supplementary data at IJE online).

Previously, fathers who started smoking early were shown to have heavier sons, indicating a possible direct effect of paternal smoking on fetal programming through the sperm epigenome, which can affect embryogenesis. We did not explicitly test this possible direct effect in our study. However, only 39 (30%) of the fathers in the exposed group had smoked during pregnancy and, after excluding these children from the analysis, 83% of our top CpGs remained Bonferroni-significant. We also controlled for this possible paternal smoking effect in the study design, as we only included in the unexposed group those children whose mother and father did not smoke.

Our results suggested that in utero exposure to smoking could have an effect on selected methylation markers which may in turn affect later health outcomes in offspring. Our approach of testing the effects of intrauterine exposures on DNA methylation in the child may serve as a model that could be extended to other exposures. One example is fetal exposure to polycyclic aromatic hydrocarbons (PAHs), which has been linked to childhood obesity. PAHs are produced during incomplete combustion and are constituents not only of cigarette smoke but also of many other sources. Results of such studies may then provide guidance to future prevention efforts tailored to limit certain exposures for pregnant women with major potential impact on public health.

In conclusion, maternal tobacco smoking during pregnancy showed genome-wide methylation differences in 35 CpGs mapped to 10 genes measured in cord blood. Our results showed remarkable similarity to previous findings, confirming the robustness of the effects. Additionally, we observed a potentially mediating role of DNA methylation in the association between maternal smoking during pregnancy and birthweight of the offspring. We were able to replicate the mediating effect for three CpGs in GFI1, which confirmed and strengthened our findings. Finally, our network and enrichment analyses indicated that smoking in the mother may induce a cellular immune response in the fetus.

Supplementary Data
Supplementary data are available at IJE online.

Funding
This methylation project in GECKO was supported by the Biobanking and Biomolecular Research Infrastructure Netherlands [CP2011-19]. The GECKO Drenthe birth cohort was funded by an unrestricted grant of Hutchison Whampoa Ltd, Hong Kong. The UK Medical Research Council and the Wellcome Trust [Grant no: 092 731] and the University of Bristol provide core support for ALSPAC. Funding for generation of DNA methylation data in ALSPAC was provided by the UK BBSRC [BB/I02575/1 and BB/I025263/1]. C.L.R. is supported by the MRC Integrative Epidemiology Unit (IEU) funded by the UK Medical Research Council [MC_UU_12013] and the University of Bristol. Funding for generation of DNA methylation data in Drenthe was provided by the UK BBSRC [BB/I02575/1 and BB/I025263/1]. C.L.R. is partially supported by the ESRC [RES-060-23-0011]: ‘The biosocial archive: transforming lifecourse research through the incorporation of epigenetic measures’. R.C.R. is funded by a Wellcome Trust 4-year PhD studentship [Grant Code: WT083431MF]. R.C.R. and C.L.R. are members of the MRC Integrative Epidemiology Unit (IEU) funded by the University of Bristol and the UK Medical Research Council [MC_UU_12013]. The Generation R Study is conducted by the Erasmus Medical Centre in close collaboration with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, the Municipal Health Service Rotterdam area, Rotterdam, the Rotterdam Homecare Foundation, Rotterdam and the Stichting Trombosedienst and Artsenlaboratorium Rijnmond (STAR), Rotterdam. The general design of Generation R Study is made possible by financial support from the Erasmus Medical Center, Rotterdam, the Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), The Netherlands Organisation for Scientific Research.
Jaenisch R, Bird A. Epigenetic regulation of gene expression.

Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG. Factors predicting overweight in US kindergarteners.

Centers for Disease Control and Prevention. Tobacco Use and Pregnancy. 2013. http://www.cdc.gov/reproductivehealth/TobaccoUsePregnancy/ (1 April 2014, date last accessed).

Sebert S, Sharkey D, Budge H, Symonds ME. The early programming of metabolic health: is epigenetic setting the missing link? Am J Clin Nutr 2011;94:1953S–58S.

Monick MM, Beach SR, Plume J et al. Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers. Am J Med Genet B Neuropsychiatr Genet 2012;159B:141–51.

Bretling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet 2011;88:450–57.

Zeiling L, Kuhnel B, Klopp N et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One 2013;8:e63812.

Guerrero-Preston R, Goldman LR, Brebi-Mieville P et al. Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics 2010;5:539–46.

Murphy SK, Adigun A, Huang Z et al. Gender-specific methylation differences in relation to prenatal exposure to cigarette smoke. Gene 2011;494:36–43.

Suter M, Abramovic A, Showalter L et al. In utero tobacco exposure epigenetically modifies placental CYP1A1 expression. Metabolism 2010;59:1481–90.

Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. Am J Respir Crit Care Med 2009;180:462–67.

Joubert BR, Habegger SE, Nilsen RM et al. 450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environ Health Perspect 2012;120:1425–31.

Markunas CA, Xu Z, Harlid S et al. Identification of DNA methylation changes in newborns related to maternal smoking during pregnancy. Environ Health Perspect 2014;122:1147–53.

Suter M, Ma J, Harris A et al. Maternal tobacco use modestly alters correlated epigenome-wide placental DNA methylation and gene expression. Epigenetics 2011;6:1284–94.

Breton CV, Siegmund KD, Joubert BR et al. Prenatal tobacco smoke exposure is associated with childhood DNA CpG methylation. PLoS One 2014;9:e99716.

Suter M, Abramovic A, Aagard-Tillery K. Genetic and epigenetic influences associated with intrauterine growth restriction due to in utero tobacco exposure. Pediatr Endocrinol Rev 2010; 8:94–102.

Engel SM, Joubert BR, Wu MC et al. Neonatal genome-wide methylation patterns in relation to birthweight in the Norwegian Mother and Child Cohort. Am J Epidemiol 2014;179:834–42.

Adkins RM, Tylavsky FA, Krushkal J. Newborn umbilical cord blood DNA methylation and gene expression levels exhibit limited association with birthweight. Chem Biodivers 2012;9:888–99.

L’Abee C, Sauer PJ, Damen M, Rake JP, Cats H, Stolk RP. Cohort Profile: the GECKO Drenthe study, overweight programming during early childhood. Int J Epidemiol 2008;37:486–89.

Aryee MJ, Jaffe AE, Corrada-Bravo H et al. Minfi: A flexible and comprehensive Bioconductor package for the analysis of...
Infinium DNA Methylation microarrays. *Bioinformatics* 2014;30:1363–69.

26. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S (eds). *Bioinformatics and Computational Biology Solutions using R and Bioconductor*. New York, NY: Springer, 2005.

27. Kile ML, Houseman EA, Baccarelli AA et al. Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. *Epigenetics* 2014;9:774–82.

28. Houseman EA, Accomando WP, Koestler DC et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics* 2012;13:86.

29. Reinus LE, Acevedo N, Joerink M et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. *PLoS One* 2012; 7: e41361.

30. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc B* 1995;57:289–300.

31. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol* 1986;51: 1173–82.

32. Soper DS. *Sobel Test Calculator for the Significance of Mediation*. 2013. http://www.danielsoper.com/statcalc (12 January 2015, date last accessed).

33. Valeri L, Vanderweele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. *Psychol Methods* 2013;18:137–50.

34. Richiardi L, Bellocco R, Zugna D. Mediation analysis in epidemiology: methods, interpretation and bias. *Int J Epidemiol* 2013;42:1511–19.

35. Dudley WN, Benuzillo JG, Carrico MS. SPSS and SAS programming for the testing of mediation models. *Nurs Res* 2004;53: 59–62.

36. Warde-Farley D, Donaldson SL, Comes O et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res* 2010;38:W214–20.

37. Vaez A, Jansen R, Prins BP, et al. An in silico post-GWAS analysis of C-reactiveprotein loci suggests an important role for interferons. *Circ Cardiovasc Genet* 2015, Mar 9. pii: CIRCGENETICS.114.000714. [Epub ahead of print.]

38. Donnelly Centre for Cellular and Biomolecular Research, University Of Toronto. *GeneMANIA*. 2014. http://genemania.org/ (19 May 2014, date last accessed).

39. Boyd A, Golding J, Macleod J et al. Cohort Profile: The ‘children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol* 2013;42:111–27.

40. Fraser A, Macdonald-Wallis C, Tilling K et al. Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. *Int J Epidemiol* 2013;42:97–110.

41. Jaddoe VW, van Duijn CM, Franco OH et al. The Generation R Study: design and cohort update 2012. *Eur J Epidemiol* 2012; 27:739–56.

42. Philibert RA, Beach SR, Lei MK, Brody GH. Changes in DNA methylation at the aryl hydrocarbon receptor repressor may be a new biomarker for smoking. *Clin Epigenetics* 2013;5:19.

43. Kobayashi T, Mitsuayama K, Yamasaki H et al. Microarray analyses of peripheral whole blood cells from ulcerative colitis patients: effects of leukocytapheresis. *Int J Mol Med* 2013;31: 789–96.

44. Venkataraman K, Von Moltke L, Greenblatt D. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. *J Clin Pharmacol* 2001;41:1149–79.

45. Wu T, Hu Y, Chen C et al. Passive smoking, metabolic gene polymorphisms, and infant birthweight in a prospective cohort study of Chinese women. *Am J Epidemiol* 2007;166:313–22.

46. Oleyt B, Walte M, Honnert U, Schillers H, Rahler M. Myosin 1G (Myo1G) is a haematopoietic specific myosin that localises to the plasma membrane and regulates cell elasticity. *FEBS Lett* 2010; 584:493–99.

47. Shimoda Y, Watanabe K. Contactins: emerging key roles in the development and function of the nervous system. *Cell Adh Migr* 2009;3:64–70.

48. Cui Y, Niziolek PJ, MacDonald BT et al. Lrp5 functions in bone to regulate bone mass. *Nat Med* 2011;17:684–91.

49. Yoon D, Kim YJ, Cui WY et al. Large-scale genome-wide association study of Asian population reveals genetic factors in FRMD4A and other loci influencing smoking initiation and nicotine dependence. *Hum Genet* 2012;131:1009–21.

50. Phelan JD, Shroyer NF, Cook T, Gebelein B, Grimes HL. Gfi1-cells and circuits: unraveling transcriptional networks of development and disease. *Curr Opin Hematol* 2010;17:300–07.

51. Duan Z, Zhang P, Montoya-Durango D, Grimes HL, Horwitz M. Gfi1 coordinates epigenetic repression of p21Cip1 and histone deacetylase l. *Mol Cell Biol* 2005;25:10338–51.

52. Cundiff P, Liu L, Wang Y et al. ERK5 MAP kinase regulates neurogenin1 during cortical neurogenesis. *PLoS One* 2009;4:e5204.

53. Suter MA, Anders AM, Aagaard KM. Maternal smoking as a model for environmental epigenetic changes affecting birthweight and fetal programming. *Mol Hum Reprod* 2012;19:1–6.

54. Briana DD, Malamitsi-Puchner A. Intrauterine growth restriction: an epigenetic view for the environmental control of the immune response. *Semin Immunol* 2009;21:337–47.

55. Stephenson T, Symonds ME. Maternal nutrition as a determinant of in vitro models. *PLoS One* 2009;4:e5204.

56. Sutter MA, Aagaard KM. Maternal smoking as a model for environmental epigenetic changes affecting birthweight and fetal programming. *Mol Hum Reprod* 2012;19:1–6.

57. Ouyang T, Wang J, Cui WY et al. Microarray profiles of peri-implantation samples reveal altered epigenetic and gene expression patterns during early development in mice with transcriptome-wide impact on gene expression. *Semin Immunol* 2013;25:194–204.

58. Aronson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on the immune system via activation of the aryl hydrocarbon receptor. *J Autoimmun* 2010;34:125–8.

59. Quintana FJ. The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. *Immunology* 2012; 138:183–89.

60. Stockinger B, Hirota K, Duarte J, Veldhoen M. External influences on the immune system via activation of the aryl hydrocarbon receptor. *Semin Immunol* 2011;23:99–105.
60. Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun 2013;41:1–5.
61. Yang IV, Schwartz DA. Epigenetic mechanisms and the development of asthma. J Allergy Clin Immunol 2012;130:1243–55.
62. Dang MN, Buzzetti R, Pozzilli P. Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes Metab Res Rev 2012;29:8–18.
63. Relton CL, Groom A, St Pourcain B et al. DNA methylation patterns in cord blood DNA and body size in childhood. PLoS One 2012;7:e31821.
64. Hayes AF. Beyond Baron and Kenny: statistical mediation analysis in the new millennium. Commun Monogr 2009;76;4:408–20.
67. Imai K, Keele L, Yamamoto T. Identification, inference and sensitivity analysis for causal mediation effects. Stat Sci 2010;25: 51–71.
68. Illumina Inc. Data Sheet: Epigenetics – Infinium HumanMethylation450 BeadChip. 2012. http://res.illumina.com/documents/products/datasheets/datasheet_humanmethylation450.pdf (12 January 2015, date last accessed).
69. Pembrey ME, Bygren LO, Kaati G et al. Sex-specific, male-line transgenerational responses in humans. Eur J Hum Genet 2006; 14:159–66.
70. Carrell DT. Epigenetics of the male gamete. Fertil Steril 2012;97: 267–74.
71. Puri D, Dhawan J, Mishra RK. The paternal hidden agenda: Epigenetic inheritance through sperm chromatin. Epigenetics 2010;5:386–91.
72. Rundle A, Hoepner I, Hassoun A et al. Association of childhood obesity with maternal exposure to ambient air polycyclic aromatic hydrocarbons during pregnancy. Am J Epidemiol 2012; 175:1163–72.